Daratumumab/VMP Combo Approved in EU for Frontline Myeloma

August 31, 2018 – The European Commission has approved daratumumab for use in combination with bortezomib, melphalan, and prednisone (VMP) for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. The approval was based on the pivotal, open-label phase III ALCYONE study, in which daratumumab plus VMP demonstrated a 50% reduction in the risk of progression or death … (leggi tutto)